Jutta Deckert
Vice President, R&D Iksuda Therapeutics
Jutta Deckert has more than 20 years of industry experience in oncology drug development with a focus on translational medicine. Currently serving as VP of Research & Development at Iksuda Therapeutics, Jutta leads the strategy and implementation of the company’s ADC pipeline, overseeing research, preclinical, and clinical activities for the advancement of novel ADC therapeutic candidates. She began her career in the ADC field at ImmunoGen, where she successfully transitioned multiple compounds into clinical development, including CD38-targeting isatuximab (approved for treating multiple myeloma) and an CD37-targeting ADC, naratuximab emtansine, for the treatment of B-cell malignancies.
Seminars
- Highlighting clinical performance of IKS014 in Phase I development for the treatment of patients with advanced HER2+ solid tumours
- Showcasing the promising preclinical profile of IKS04 targeting CA242 in gastrointestinal cancer
- Addressing the concept of ADC sequencing in future treatment paradigms
As an increasingly diverse array of ADCs containing different payloads and linkers are developed to tackle different tumour targets, understanding how bioconjugate design contributes and accumulates to performance, especially in the clinic, is vital to set up your therapy for success
Take part in this workshop exploring case-study examples to contextualise and understand the performance of different ADC designs to understand what really makes a clinically effective ADC
Workshop highlights include:
- Accurately correlating and characterising antibody, linker, payload, and overall conjugate contributions to ADC clinical performance
- Delving into ADC clinical case studies to understand differentiated design impact on clinical safety and efficacy profiles
- Finding the right match: optimising ADC design to optimise payload target pairing
